Biology and Chemistry of Thrombopoietic Agents

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 243-248

  Kuter, David J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 2; CORTICOSTEROID; ELTROMBOPAG; HEMATOLOGIC AGENT; IMMUNOGLOBULIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; ROSUVASTATIN; STAT5 PROTEIN; THROMBOPOIETIC AGENT; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIDE EFFECT; SINGLE DRUG DOSE; SPLENECTOMY; STRUCTURE ACTIVITY RELATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; UNSPECIFIED SIDE EFFECT;

BLOOD PLATELETS; HUMANS; MEGAKARYOCYTES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOPOIETIN;

EID: 77953896640     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.02.005     Document Type: Article

References (31)

1. Kelemen E., Cserhati I., Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958, 20:350-355.
2. Kaushansky K., Lok S., Holly R.D., et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994, 369:568-571.
3. de Sauvage F.J., Hass P.E., Spencer S.D., et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369:533-538.
4. Vigon I., Mornon J.P., Cocault L., et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992, 89:5640-5644.
5. Bartley T.D., Bogenberger J., Hunt P., et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994, 77:1117-1124.
6. Kuter D.J., Beeler D.L., Rosenberg R.D. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994, 91:11104-11108.
7. Kato T., Ogami K., Shimada Y., et al. Purification and characterization of thrombopoietin. J Biochem 1995, 118:229-236.
8. Kuter D.J., Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002, 100:3457-3469.
9. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
10. Feese M.D., Tamada T., Kato Y., et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A 2004, 101:1816-1821.
11. Stoffel R., Wiestner A., Skoda R.C. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996, 87:567-573.
12. Fielder P.J., Gurney A.L., Stefanich E., et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996, 87:2154-2161.
13. Columbyova L., Loda M., Scadden D.T. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995, 55:3509-3512.
14. Sabath D.F., Kaushansky K., Broudy V.C. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999, 94:365-367.
15. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006, 354:2034-2045.
16. Carver-Moore K., Broxmeyer H.E., Luoh S.M., et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996, 88:803-808.
17. Harker L.A., Carter R.A., Marzec U.M., et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy [abstract]. Blood 1998, 92:707a.
18. Harker L.A., Marzec U.M., Hunt P., et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996, 88:511-521.
19. Cwirla S.E., Balasubramanian P., Duffin D.J., et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276:1696-1699.
20. Nplate prescribing information 2008, Amgen, Inc.
21. Broudy V.C., Lin N.L. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004, 25:52-60.
22. Wang B., Nichol J.L., Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharm Therapeut 2004, 76:628-638.
23. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
24. Kuter D., Rummel M., Boccia R., et al. Comparison of splenectomy and treatment failure incidence in nonsplenectomized patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care: 1-year treatment and 6-month safety follow-up. Blood 2009, 114:284.
25. Duffy K.J., Darcy M.G., Delorme E., et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001, 44:3730-3745.
26. Erickson-Miller C.L., DeLorme E., Tian S.S., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005, 33:85-93.
27. Promacta prescribing information 2008, GlaxoSmithKline, Inc, Thousand Oaks, CA.
28. Erickson-Miller C.L., Delorme E., Tian S.S., et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27:424-430.
29. Yamane N., Tanaka Y., Ohyabu N., et al. Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor. Eur J Pharmacol 2008, 586:44-51.
30. Jenkins J.M., Williams D., Deng Y., et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109:4739-4741.
31. Erhardt J.A., Erickson-Miller C.L., Aivado M., Abboud M., Pillarisetti K., Toomey J.R. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37:1030-1037.